Abbott Laboratories Earnings

Abbott Laboratories’s revenue jumped 4.42% since last year same period to $11459Mn in the Q4 2025. On a quarterly growth basis, Abbott Laboratories has generated 0.79% jump in its revenue since last 3-months.

Abbott Laboratories’s net profit fell -80.76% since last year same period to $1776Mn in the Q4 2025. On a quarterly growth basis, Abbott Laboratories has generated 8.03% jump in its net profits since last 3-months.

Abbott Laboratories’s net profit margin fell -81.57% since last year same period to 15.5% in the Q4 2025. On a quarterly growth basis, Abbott Laboratories has generated 7.18% jump in its net profit margins since last 3-months.

Abbott Laboratories’s price-to-earnings ratio after this Q4 2025 earnings stands at 28.18.

Abbott Laboratories’s earning per share (EPS) estimates for the current quarter stand at 1.15 - a -22.82% fall from last quarter’s estimates.

Abbott Laboratories’s earning per share (EPS) estimates for the current year stand at 1.15.

Abbott Laboratories’s earning per share (EPS) jumped 11.94% since last year same period to 1.5 in the Q4 2025. This indicates that the Abbott Laboratories has generated 11.94% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Abbott Laboratories’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Abbott Laboratories’s return on equity (ROE) stands at 0.13.

Abbott Laboratories declared 0.59 dividend per share during the earnings announcement for Q4 2025.